logo
What is the infected blood scandal and how much compensation will victims get?

What is the infected blood scandal and how much compensation will victims get?

Yahoo07-05-2025

Government officials have been called to give evidence to a special session of the infected blood inquiry amid "grave concerns" about the speed of compensation payments.
The inquiry's chair, Sir Brian Langstaff, made the unusual decision to take fresh evidence nearly a year after his final report into the scandal.
More than 30,000 people in the UK were infected with HIV and hepatitis C after being given contaminated blood products in the 1970s and 1980s.
As many as 140,000 bereaved parents, children and siblings of victims may also be able to claim compensation in their own right.
Who was given infected blood and how many died?
Two main groups of NHS patients were affected by what has been called the biggest treatment disaster in the history of the NHS.
Firstly, haemophiliacs - and those with similar disorders - who have a rare genetic condition which means their blood does not clot properly.
People with haemophilia A have a shortage of a clotting agent called Factor VIII, while people with haemophilia B do not have enough Factor IX.
In the 1970s, a new treatment using donated human blood plasma was developed to replace these clotting agents.
But entire batches were contaminated with deadly viruses.
After being given the infected treatments, about 1,250 people in the UK with bleeding disorders went on to develop both HIV and hepatitis C, including 380 children.
About two-thirds later died of Aids-related illnesses. Some unintentionally gave HIV to their partners.
Another 2,400 to 5,000 people developed hepatitis C on its own, which can cause cirrhosis and liver cancer.
It is difficult to know the exact number of people infected with hepatitis C, partly because it can take decades for symptoms to appear.
A second group of patients were given contaminated blood transfusions after childbirth, surgery or other medical treatment between 1970 and 1991.
The inquiry estimates that between 80 and 100 of these people were infected with HIV, and about 27,000 with hepatitis C.
In total, it is thought about 2,900 people have died.
What did the infected blood inquiry say?
Announcing its findings in May 2024, the inquiry said victims had been failed "not once, but repeatedly", and that the risk of viral infections in blood products had been known since 1948.
Inquiry chairman Sir Brian Langstaff said there had been a lack of openness from the authorities and elements of "downright deception", including the destruction of documents.
He said half-truths were also told, so people did not know about the risk of their treatment, the availability of alternatives, or even whether they were infected.
"This disaster was not an accident," said Sir Brian. "The infections happened because those in authority - doctors, the blood services and successive governments - did not put patient safety first."
The Inquiry report said:
too little was done to stop importing blood products from abroad, which used blood from high-risk donors such as prisoners and drug addicts
in the UK, blood donations were accepted from high-risk groups such as prisoners until 1986
blood products were not heat-treated to eliminate HIV until the end of 1985, although the risks were known in 1982
there was too little testing to reduce the risk of hepatitis, from the 1970s onwards
How much compensation will infected blood victims get?
In October 2024, Chancellor Rachel Reeves said that the government had set aside £11.8bn to pay compensation to victims.
It set up an independent arms-length body called the Infected Blood Compensation Authority (IBCA) to administer payments.
Both those infected by contaminated blood products and those affected by the scandal - such as partners, parents, children and siblings - can claim compensation for the impact on their lives.
Payments are exempt from tax, and do not affect benefits.
The final amounts for individuals are assessed against five criteria: harm caused, social impact from stigma and isolation, impact on autonomy and private life, care costs and financial loss.
Outlining the compensation scheme after the inquiry reported in May 2024, the then-Conservative government suggested how much people might receive:
a person infected with HIV could expect to get compensation of between £2.2m and £2.6m
those with a chronic hepatitis C infection, defined as lasting more than six months, could expect to receive between £665,000 and £810,000
the partner of someone infected with HIV who is still alive today could expect to receive about £110,000, while a child could get £55,000
Compensation payments will go to the estate of infected people who have died.
But if a partner or relative who might be entitled to a payment has died, their estate will not receive any money.
Have any compensation payments already been made?
In late 2022, following advice from the inquiry, the Conservative government made interim payments of £100,000 each to about 4,000 surviving victims and bereaved partners. A second interim payment of £210,000 was paid to those infected in June 2024.
In October 2024, the government said more relatives of those who died could also apply for £100,000 interim payments if the money had not already been claimed.
The IBCA said, as of 6 May:
677 people have been invited to claim final compensation
160 compensation payments totalling £150.2m have been offered
106 compensation payments totalling £96.6m have been made
An IBCA spokesman said its priority remained "paying as many people as soon as possible". It plans to ask an extra 100 individuals to start their claims every week from May 2025.
It has also announced that it would start to prioritise payments to those who had less than 12 months left to live due to any medical condition.
Victims and their relatives have criticised the time taken to make payments, and what they say is a lack of transparency about the claims process.
On 9 April Sir Brian said he would re-open the inquiry on 7 and 8 May to take evidence about the speed of compensation payments.
Government officials, including the cabinet office minister Nick Thomas-Symonds, will give evidence under oath and the sessions will be filmed and streamed online.
Sir Brian said: "The decision to hold hearings has not been taken lightly. It reflects the gravity of concerns expressed consistently and repeatedly to the inquiry.
"People infected and affected do not have time on their side."
How did the infected blood scandal happen?
In the 1970s, the UK was struggling to meet the demand for blood-clotting treatments, so imported supplies from the US.
But much of the blood was bought from high-risk donors such as prison inmates and drug-users.
Factor VIII was made by pooling plasma from tens of thousands of donors.
If just one was carrying a virus, the entire batch could be contaminated.
UK blood donations were not routinely screened for hepatitis C until 1991, 18 months after the virus was first identified.
When did authorities know about infected blood?
By the mid-1970s, there were repeated warnings that imported US Factor VIII carried a greater risk of infection.
However, attempts to make the UK more self-sufficient in blood products failed, so the NHS continued using foreign supplies.
Campaigners say haemophiliacs could have been offered an alternative treatment called Cryoprecipitate. This was much harder to administer, but was made from the blood plasma of a single donor, lowering the infection risk.
BBC News has also uncovered evidence children were infected with hepatitis C and HIV after being placed on clinical trials of new treatments - often, without their family's consent.
As late as November 1983, the government insisted there was no "conclusive proof" that HIV could be transmitted in blood, a line robustly defended by former Conservative health minister Ken Clarke when he appeared before the inquiry.
What happened in other countries affected by infected blood?
Many other countries were affected, although some - including Finland - used older treatments until much later rather than switch to Factor VIII, which minimised HIV infections.
Delivering the findings of the inquiry, Sir Brian criticised UK government claims in the 1990s that screening for hepatitis C began as soon as the technology was available.
He said that 23 other countries - including Japan, Finland and Spain - introduced the screening before the UK.
In the US, companies that supplied infected products have paid out millions in out-of-court settlements.
Politicians and drug companies have been convicted of negligence in countries including France and Japan.
In his evidence to the inquiry, former health secretary Andy Burnham suggested there may be grounds for charges of corporate manslaughter in the UK.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test
Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test

Yahoo

time2 hours ago

  • Yahoo

Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test

A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment. Rebeca Proctor, 41, from Carlisle, was diagnosed with stage 4 non-small-cell lung cancer in January. She was able to begin treatment earlier thanks to a new NHS liquid biopsy blood test, which identified a specific genetic mutation. Ms Proctor said: "When I found out I had stage 4 cancer it felt like I'd been punched in the gut, I was scared – I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children – it was just heart-breaking to think about. "But the medication has given me my life back and my kids have got their mum back. "I'm taking it day by day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back. "I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading – we'll keep fighting this and dealing with what's been thrown at us." The liquid biopsy revealed she had an ALK genetic mutation, allowing her to start a targeted therapy, brigatinib. A traditional tissue biopsy confirmed the result around 10 days later. Ms Proctor is under the care of Dr Sally Hall, a consultant medical oncologist at the Northern Centre for Cancer Care in North Cumbria. The new blood test, now available across the NHS in England, detects fragments of tumour DNA in the bloodstream. It identifies genetic mutations that can guide personalised cancer treatment. NHS England recently announced that up to 15,000 patients with suspected lung cancer could benefit from the test each year. An NHS pilot found that lung cancer patients could start targeted treatment up to 16 days sooner using the liquid biopsy compared to standard tissue biopsies. The pilot also showed that some patients were able to avoid unnecessary chemotherapy and its side effects, improving their quality of life. Professor Peter Johnson, NHS national clinical director for cancer, said: "Liquid biopsies are leading us into a new era of personalised cancer care and it's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country. "Cutting-edge genomic testing is helping us deliver more targeted and kinder care for patients, enabling some to avoid more intensive treatments such as further chemotherapy, which can have a huge impact." Professor Alastair Greystoke, co-clinical lead of the ctDNA pilot and honorary medical oncologist at Newcastle Hospitals, said: "This is the first ever national implementation of a 'liquid biopsy first' approach to the diagnosis and treatment of a cancer." "Not only has it led to faster and more precise treatment for patients with lung cancer, but we have also been able to show that this is a cost-effective measure for the NHS and set up the framework to evaluate this in other cancers going forward." Professor Dame Sue Hill, chief scientific officer for England, said: "This represents a real step-change in care for eligible lung and breast cancer patients on the NHS. "The liquid biopsy testing enables genomic mutations in the fragments of cancer that enter the bloodstream of these patients to be detected. "This testing is transforming care and helping clinicians match patients earlier, especially when cancer tissue may not be available, with potentially life-extending targeted therapies rapidly and with greater precision."

Pregnant women warned against using weight-loss jabs
Pregnant women warned against using weight-loss jabs

Yahoo

time3 hours ago

  • Yahoo

Pregnant women warned against using weight-loss jabs

Women using weight-loss jabs are being advised to stop if they are trying for a baby, have fallen pregnant or are breastfeeding. Drug safety experts in the UK say it's not known whether taking the medicines, such as Wegovy and Mounjaro, could harm an unborn baby. The advice already appears in patient information leaflets that come with the medicines. But there are concerns that the growing popularity of 'skinny jabs' means many women aren't using the drugs safely or getting the right advice. Natasha Major, 26, started using Mounjaro to lose weight before planning to try for her third baby in a few years' time, but was shocked six weeks later to find she was pregnant. She was taking the contraceptive pill at the time. "I have polycystic ovaries as well, so I can't get pregnant easily or quickly. So it was an even bigger shock that I had, which didn't make any sense to me," she says. She then worried she could be harming the baby or it wouldn't develop properly, so she rang her GP for advice, who told her to stop taking it. "We're over the initial shock now and really happy, just wasn't expected," she says. "The last injection I took, I found out about the pregnancy three hours later and haven't taken it since then. "I've had an early scan to make sure the pregnancy was viable and okay - baby had a little heartbeat and everything looks good," Natasha says. The UK drugs regulator, as well as doctors and pharmacists, are worried that popular GLP-1 medicines, known as Wegovy, Mounjaro, Saxenda, Victoza and Ozempic, are not being used safely. These prescription medicines, which are licensed to treat obesity (and Ozempic for type 2 diabetes), make people feel full by mimicking a hormone released after eating. Mounjaro also acts on another hormone linked to appetite and blood sugar control. They are only available on the NHS to people with a very high BMI, but such is the demand for them that many people are buying them from unregulated sellers on social media or from beauty salons, without any medical advice, as a quick fix to lose weight. How do weight loss drugs like Mounjaro and Wegovy work? Women share their bittersweet experience after taking weight-loss drugs As a precaution, the Medicines and Healthcare products Regulatory Agency (MHRA) says women should use contraception while taking GLP-1 medicines and for a certain period afterwards before trying to become pregnant - two months for Wegovy and Ozempic, and one month for Mounjaro. It also advises that those using Mounjaro and taking an oral contraceptive should also use a condom for four weeks after starting the drug, or switch to another method such as the coil or implant. Weight-loss jabs may make the contraceptive pill less likely to work in those who are overweight or obese, the MHRA says. Women should be told this information when they starting taking the jabs, but there are fears the message is not getting through. Natasha bought Mounjaro online and says she "can't remember reading anything about contraception on there". The MHRA has produced new guidance on weight-loss jabs for people taking them. It's acted now because of a very small number of reports of unintended pregnancies and complications in pregnancy made to its Yellow Card scheme, where the public can report suspected side-effects of medicines. Dr Alison Cave, chief safety officer at the MHRA, said there was evidence from animal studies "that these medicines may harm the unborn baby". "But we don't know whether we have the same effects in humans, so much more data is needed to determine that." Women of child-bearing age are usually not included in clinical trials, which is why there is a lack of safety information for them. "If you are taking this medicine and you are pregnant, you should talk to your doctor about stopping the medicine as soon as possible," she said. Sukhi Basra, vice-chairwoman of the National Pharmacy Association, said women should visit their pharmacist for advice if they are confused about when to stop using the drugs. When it comes to accessing contraception, BPAS, the British Pregnancy Advisory Service, says women in the UK "face significant challenges" when trying to access their method of choice. A lack of appointments, long waiting lists and high costs are just some of the barriers they face, BPAS said, as it called for a better plan for providing the choice women need. 'Skinny jabs' too easy to order online, GP warns Weight-loss drugs tested in head-to-head trial 'WeightWatchers set me up to fail' - Why diet industry is losing to jabs like Ozempic

WH budget chief pressed on PEPFAR funds, says Africa ‘needs to absorb more of the burden'
WH budget chief pressed on PEPFAR funds, says Africa ‘needs to absorb more of the burden'

Yahoo

time5 hours ago

  • Yahoo

WH budget chief pressed on PEPFAR funds, says Africa ‘needs to absorb more of the burden'

Office and Management Budget Director Russell Vought on Wednesday was pressed on proposed cuts to the President's Emergency Plan for AIDS Relief (PEPFAR) pursued as part of a new rescissions request from the Trump administration. During a budget hearing Wednesday, Vought defended proposed reductions as targeting items like 'teaching young children how to make environmentally friendly reproductive health decisions' and efforts he claimed were aimed at strengthening 'the resilience of lesbian, gay, bisexual, transgender, intersex and queer global movements.' 'We can find waste, fraud and abuse there that the American people would not support, and it's one of the reasons why it's in the package, but it will not lead to life saving treatment being denied,' he said during the hearing. Congress, under the Biden administration, appropriated approximately $7 billion for PEPFAR in fiscal 2024. The program is considered to be one of America's most consequential programs in Africa and is credited with saving 25 million lives and scaling back the AIDS epidemic. During the hearing, Rep. Mark Alford (R-Mo.) in a follow-up question pressed Vought again about his comments and potential cuts to prevention efforts. 'Aside from the crazy woke programs, which I agree should be stripped,' Alford asked, 'is there any other prevention program, not treatment, but prevention program listed in this rescission package, which is not of a woke nature?' Vought said in response that the administration seeks to scale 'down the program as it pertains to the types of organizations that are providing the examples of the waste, fraud and abuse.' But he also said 'the prevention itself is where an analytical look needs to be done.' 'There's life saving treatment after you already have HIV, but there are prevention programs that PEPFAR does, which are not of the woke nature, which can prevent someone from getting HIV,' Alford countered. 'Are those programs going to survive?' 'It is something that our budget will be very trim on because we believe that many of these nonprofits are not geared toward the viewpoints of the administration, and we're $37 trillion in debt,' Vought responded. 'So, at some point, the continent of Africa needs to absorb more of the burden of providing this health care.' The moment comes as the prospect of PEPFAR cuts has prompted concern from some congressional Republicans as part of a larger request sent by the Trump administration to cut more than $9 billion in congressionally approved funds for foreign aid and public broadcasting programs. Senate Appropriations Committee Chair Susan Collins (R-Maine) has also voiced opposition to cutting PEPFAR, saying Wednesday that the idea makes 'no sense' to her 'whatsoever.' 'Given the extraordinary record of PEPFAR in saving lives, it has literally saved millions of lives, and so I do not see a basis for cutting it,' she said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store